Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Simvastatin: the clinical profile.

J F Walker1

  • 1Merck Sharp & Dohme Research Laboratories, Rahway, New Jersey 07065.

The American Journal of Medicine
|October 16, 1989
PubMed
Summary
This summary is machine-generated.

Simvastatin effectively lowers cholesterol in patients with primary hypercholesterolemia. This HMG-CoA reductase inhibitor is well-tolerated, with mild side effects and a favorable safety profile for long-term use.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Global transcriptional differences in myokine and inflammatory genes in muscle of mature steer progeny are related to maternal lactation diet and muscle composition.

Physiological genomics·2018
Same author

Increased daily movement associates with reduced mortality among COPD patients having systemic inflammation.

International journal of clinical practice·2016
Same author

Monitoring the long-term safety of lipid lowering therapy.

The International journal of risk & safety in medicine·2013
Same author

Pulmonary nociceptors are potentially connected with neuroepithelial bodies.

Advances in experimental medicine and biology·2006
Same author

Pulmonary sensory and reflex responses in the mouse.

Journal of applied physiology (Bethesda, Md. : 1985)·2006
Same author

Water and solute mass balance of five small, relatively undisturbed watersheds in the U.S.

The Science of the total environment·2005
Same journal

GLP-1 Receptor Agonists and Age-related Macular Degeneration Risk in Diabetes or Non-diabetic Obesity: A Retrospective Cohort Study.

The American journal of medicine·2026
Same journal

Marijuana Use and Acute Myocardial Infarction: Mechanistic Insights, Clinical Implications, and Emerging Challenges.

The American journal of medicine·2026
Same journal

Cave Canem - Beware of the Dog.

The American journal of medicine·2026
Same journal

Risk Factors for 30-day Hospital Readmission After Hospital-at-Home Treatment of Acute Pyelonephritis.

The American journal of medicine·2026
Same journal

Mesenteric Panniculitis.

The American journal of medicine·2026
Same journal

Hypercalcemia and hyperferritinemia in a patient with Graves' disease disease.

The American journal of medicine·2026
See all related articles

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Clinical Therapeutics

Background:

  • Simvastatin is a hydroxymethylglutaryl-coenzyme A reductase inhibitor.
  • Primary hypercholesterolemia is a condition characterized by elevated cholesterol levels.
  • Statins are a class of drugs used to lower cholesterol.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of simvastatin in patients with primary hypercholesterolemia.
  • To assess the impact of simvastatin on lipid profiles, including total cholesterol, LDL cholesterol, and HDL cholesterol.
  • To document the safety profile of simvastatin, including adverse experiences and laboratory abnormalities.

Main Methods:

  • A study involving over 1,800 patients with primary hypercholesterolemia.

Related Experiment Videos

  • Treatment duration of up to two years.
  • Dosage range of 10 to 40 mg once daily.

    • Main Results:

    • Reductions of up to 30% in total cholesterol and 40% in LDL cholesterol.
    • Increases of approximately 10% in HDL cholesterol.
    • Common adverse effects included mild gastrointestinal issues and headache; elevations in creatine kinase and hepatic transaminase levels were infrequent and generally manageable.

    Conclusions:

    • Simvastatin is an effective and well-tolerated treatment for primary hypercholesterolemia.
    • The drug demonstrates a favorable safety profile with manageable side effects.
    • Simvastatin is a promising addition to the therapeutic options for managing high cholesterol.